Research programme: anti-fungal drugs - REVOLUTION Medicines

Drug Profile

Research programme: anti-fungal drugs - REVOLUTION Medicines

Latest Information Update: 24 Feb 2015

Price : $50

At a glance

  • Originator University of Illinois at Urbana-Champaign
  • Developer REVOLUTION Medicines
  • Class Small molecules
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Mycoses

Most Recent Events

  • 04 Feb 2015 REVOLUTION Medicines entered into an exclusive license agreement with the University of Illinois Urbana-Champaign, for the lead anti-fungal programme and the building block synthesis platform technology
  • 04 Feb 2015 Early research in Mycoses in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top